TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29551346

Group type: EXPERIMENTAL
Intervention: Desensitizing-containing 10% carbamide peroxide gel (3% potassium nitrate and 0.2% sodium fluoride)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desensitizing-free 10% carbamide peroxide gel
Number of subjects: 60
Study: 26750677

Group type: EXPERIMENTAL
Intervention: Macintosh (MC) laryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: McGrath (MG) laryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Truview™ laryngoscope
Number of subjects: 60
Study: 24509697

Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing L. reuteri strain (Prodentis)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No probiotic tablet treatment (Control Group 2)
Number of subjects: 38
Study: 22103571

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study: 21051677

Group type: EXPERIMENTAL
Intervention: High-dose interferon-{alpha} treatment for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-dose interferon-{alpha} treatment for 4 weeks
Number of subjects: 46
Study: 17097342

Group type: EXPERIMENTAL
Intervention: Real-rTMS (90% of resting motor threshold, 10 Hz, 450 pulses/day for 10 consecutive days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Real-rTMS
Number of subjects: 13
Study: 16401946

Group type: EXPERIMENTAL
Intervention: Protocol A (Ceftriaxone, Metronidazole, and aminoglycoside)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Protocol B (Ceftriaxone and Metronidazole)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 59

Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 59
Study: 12100574

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline PBC patients
Number of subjects: 28
Study: 10539749

Group type: EXPERIMENTAL
Intervention: Prepared Meal Plan (PMP; n = 244)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Self-Selected Diet (SSD; n = 247)
Number of subjects: 491
Study: 7573849

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 5 mg aerosol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 114
Study: 2154942

Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Suture technique
Number of subjects: 59

Group type: COMPARATOR
Intervention: Staple technique
Number of subjects: 59

Group type: COMPARATOR
Intervention: All techniques (BAR, suture, staple)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BAR
Number of subjects: 59
Study: 7428417

Group type: EXPERIMENTAL
Intervention: Mefruside
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Debrisoquin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of debrisoquin and mefruside
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30796587

Group type: EXPERIMENTAL
Intervention: Intraoral scan (IOS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional impression (CI)
Number of subjects: 19
Study: 28657492

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28011809

Group type: EXPERIMENTAL
Intervention: Low TT group receiving 430 mg of 70% pure TTs (300 mg TT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High TT group receiving 860 mg of 70% pure TTs (600 mg TT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group receiving 860 mg olive oil
Number of subjects: 0
Study: 24961753

Group type: EXPERIMENTAL
Intervention: Evacetrapib 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21983371

Group type: EXPERIMENTAL
Intervention: Methylprednisolone infusion (n = 55)
Number of subjects: 79
Study: 19578220

Group type: EXPERIMENTAL
Intervention: Plapheron LB in dose of 0.028 mg/kg two times a day sublingually for ten days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ordinary program of intensive therapy
Number of subjects: 94
Study: 17518892

Group type: EXPERIMENTAL
Intervention: Video-centred teaching program
Number of subjects: 123

Group type: COMPARATOR
Intervention: Illustrated poster teaching
Number of subjects: 123
Study: 15041602

Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (FICB) with ropivacaine 0.2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 20
Study: 11314833

Group type: EXPERIMENTAL
Intervention: Intramuscular metaraminol (0.1 mg x kg(‐1))
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravenous boluses (0.01 mg x kg(‐1))
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Infusion (0.05 mg x kg(‐1) x h(‐1))
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 52
Study: 9041052

Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor‐I (IGF‐I) administration, 40 micrograms/kg of body weight/day, for 1 week
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, then 0.250 IU/kg of body weight/week, for 24 months
Number of subjects: 22
Study: 7957464

Group type: EXPERIMENTAL
Intervention: Wide‐spectrum antibiotic therapy with macrolide and mepartricin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 77
Study: 3479447

Group type: EXPERIMENTAL
Intervention: Trauner's open method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brown's closed method
Number of subjects: 0
Study: 28385953

Group type: EXPERIMENTAL
Intervention: Safety promotion intervention (n=91)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Attention-control group (n=186)
Number of subjects: 277
Study: 28228162

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination
Number of subjects: 404

Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 404
Study: 26237742

Group type: EXPERIMENTAL
Intervention: MenACWY-TT booster dose
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Number of subjects: 872

Group type: COMPARATOR
Intervention: MenACWY-TT
Number of subjects: 872
Study: 24192207

Group type: EXPERIMENTAL
Intervention: Raloxifene (not specified dosage or duration)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1245
Study: 21068346

Group type: EXPERIMENTAL
Intervention: 500 mL orange juice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 500 mL control drink plus hesperidin (CDH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500 mL control drink plus placebo (CDP)
Number of subjects: 24
Study: 18978616

Group type: EXPERIMENTAL
Intervention: Whole-body low-intensity resistance training with slow movement and tonic force generation (LST)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training with normal speed (HN)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary control group (CON)
Number of subjects: 36
Study: 14627972

Group type: EXPERIMENTAL
Intervention: Intermittent hyperkalaemic undiluted warm blood anterograde cardioplegia (AC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Continuous hyperkalaemic undiluted warm blood retrograde cardioplegia (RC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermittent, hyperkalaemic, diluted cold blood (15 degrees C), anterograde cardioplegia (CC)
Number of subjects: 69
Study: 9921604

Group type: EXPERIMENTAL
Intervention: Methods of extracting estimates of log hazard ratio and its variance
Number of subjects: 0
Study: 9050559

Group type: EXPERIMENTAL
Intervention: ClearView Uterine Manipulator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cohen cannula
Number of subjects: 50
Study: 2235671

Group type: EXPERIMENTAL
Intervention: Single bolus injection of heparin (3000 to 12,000 U) administered prior to hemodialysis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Individualized dose
Number of subjects: 17
Study: 28810

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiazide diuretic (Bendrofluazide)
Number of subjects: 0
Study: 31542876

Group type: EXPERIMENTAL
Intervention: PAM50 subtypes
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Luminal B subtype
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: 13-gene hypoxia signature
Number of subjects: 1723
Study: 31335301

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/levonorgestrel (EE/LNG) 30/150 μg co-administered with atazanavir/cobicistat (ATV/COBI) 300/150 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (Atazanavir/cobicistat alone)
Number of subjects: 6
Study: 28072447

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid-enriched diet (ProSure®), 600 kcal with 2.2 g eicosapentaenoic acid, for 7 days before and 21 days after surgery
Number of subjects: 126
Study: 26103654

Group type: EXPERIMENTAL
Intervention: Drug treatment + patient education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drug treatment only
Number of subjects: 100
Study: 23683475

Group type: COMPARATOR
Intervention: Clinical model without kallikrein markers
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Clinical model with kallikrein markers
Number of subjects: 392
Study: 21243370

Group type: EXPERIMENTAL
Intervention: PVD and removal of the ILM (group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical induction of posterior vitreous detachment (PVD) (group I)
Number of subjects: 40
Study: 18976313

Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOLs
Number of subjects: 60

Group type: COMPARATOR
Intervention: AcrySof Natural IOLs
Number of subjects: 60
Study: 18004124

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-400 mg/d)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 15138475

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 2 years
Number of subjects: 167

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Untreated patients with cyclin D1 high tumors
Number of subjects: 167
Study: 11472654

Group type: EXPERIMENTAL
Intervention: Immediate provisional protocol for single-tooth implant replacement
Number of subjects: 24
Study: 9603636

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 105

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 105
Study: 8091964

Group type: EXPERIMENTAL
Intervention: CMD women
Number of subjects: 168

Group type: COMPARATOR
Intervention: CMD men
Number of subjects: 168
Study: 3401061

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with closure (PGV)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Closure alone
Number of subjects: 78
Study: 31783004

Group type: EXPERIMENTAL
Intervention: Group B: 3.6 mL of articaine and 1 mL of dexamethasone (4‐mg/mL solution) with 1 mL of saline solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C: 3.6 mL of articaine with 2 mL of dexamethasone (8‐mg/mL solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group A: 3.6 mL of articaine mixed with 2 mL of saline solution
Number of subjects: 60
Study: 30924413

Group type: EXPERIMENTAL
Intervention: Home ovulation test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predicted day of ovulation based on average menstrual cycle
Number of subjects: 0
Study: 27775471

Group type: EXPERIMENTAL
Intervention: 4-week diet and physical activity intervention (n = 17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Assessment-only control group (n = 15)
Number of subjects: 32
Study: 24888221

Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 59
Study: 23617871

Group type: EXPERIMENTAL
Intervention: Participation in recovery-oriented activities
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Syringe exchange program (SEP) participation
Number of subjects: 240
Study: 21267039

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5% 10 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 9 mL of 0.5% lidocaine mixed with 1 mL of steroid (either betamethasone [6 mg] or methylprednisolone [40 mg])
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful group (patients achieving significant pain relief and functional status improvement)
Number of subjects: 120
Study: 19689825

Group type: EXPERIMENTAL
Intervention: 80 Gy in 40 fractions over 8 weeks (arm A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 62 Gy in 20 fractions over 5 weeks (arm B)
Number of subjects: 162
Study: 17339189

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (PBSCT) after induction and consolidation chemotherapy with BAVC regimen.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Induction therapy with mitoxantrone, etoposide, and cytarabine (MICE) with or without G-CSF; consolidation therapy with mini-ICE.
Number of subjects: 61
Study: 14668149

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (EMG biofeedback training plus conventional exercise programme)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional exercise programme only (Control)
Number of subjects: 36
Study: 11295361

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Red wine
Number of subjects: 18

Group type: COMPARATOR
Intervention: White wine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alcohol-containing beverages (red and white wine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: All beverages
Number of subjects: 18
Study: 9496496

Group type: EXPERIMENTAL
Intervention: Dilatation (DILAT Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esophagocardiomyotomy (Group OP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 40
Study: 7922793

Group type: EXPERIMENTAL
Intervention: Injectable salmon calcitonin (50 IU)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Injectable calcitonin analogue ASC 710 (0.2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral ASC 710 (20 mg)
Number of subjects: 6
Study: 3165972

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 40
Study: 29516490

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 29151561

Group type: EXPERIMENTAL
Intervention: Positive psychotherapy program (n=28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual treatment in community centers (n=29)
Number of subjects: 57
Study: 25935793

Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 481

Group type: COMPARATOR
Intervention: 6 months of adjuvant trastuzumab
Number of subjects: 481
Study: 23968366

Group type: EXPERIMENTAL
Intervention: Structured lifestyle and medication treatment by practice nurses with additional self‐monitoring
Number of subjects: 179

Group type: COMPARATOR
Intervention: Structured lifestyle and medication treatment by practice nurses without additional self‐monitoring
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Addition of or dose change in lipid lowering or antihypertensive medications
Number of subjects: 179
Study: 20881473

Group type: EXPERIMENTAL
Intervention: Community-based, multicomponent HIV and reproductive health intervention, with exposure to at least 10 intervention sessions.
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Community-based, multicomponent HIV and reproductive health intervention.
Number of subjects: 4684

Group type: COMPARATOR
Intervention: Control group (deferred implementation of the intervention).
Number of subjects: 4684
Study: 19100928

Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization (Group IC; n = 109)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Continuous bladder catheterization (Group CC; n = 100)
Number of subjects: 209
Study: 16337368

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 0
Study: 12769155

Group type: EXPERIMENTAL
Intervention: 2% polyvinylpyrrolidone (PVP) solution
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.9% NaCl solution
Number of subjects: 39
Study: 11081985

Group type: EXPERIMENTAL
Intervention: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang) taken three times daily for a minimum of 3 days and a maximum of 8 days (pilot study) or for exactly three days (phase III study)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 9352698

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.6 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tamsulosin (all doses)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 126
Study: 8463026

Group type: EXPERIMENTAL
Intervention: Walking (WALK) group exercised 5 d.wk-1 for 30-40 min per session at 60.0 +/- 1.9% heart rate reserve
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calisthenics control (CAL) group engaged in mild musculoskeletal exercise
Number of subjects: 30
Study: 4037540

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg bolus followed by continuous infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29677007

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (unblinded)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intermittent glucose monitoring (blinded)
Number of subjects: 77
Study: 26995374

Group type: EXPERIMENTAL
Intervention: Metoprolol 25 to 100 mg BID
Number of subjects: 248

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 248
Study: 24438128

Group type: EXPERIMENTAL
Intervention: Epley manoeuvre
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham manoeuvre
Number of subjects: 44
Study: 22357892

Group type: EXPERIMENTAL
Intervention: Computer‐assisted cognitive rehabilitation of attention and information processing and executive functions (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without cognitive rehabilitation (n = 10)
Number of subjects: 20
Study: 19118910

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 24
Study: 17727860

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (overall)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (in patients without portacaval shunt or plasmapheresis)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Atorvastatin (crossover treatment)
Number of subjects: 44
Study: 15851919

Group type: EXPERIMENTAL
Intervention: bivalent rgp120 vaccine
Number of subjects: 5403
Study: 14646367

Group type: EXPERIMENTAL
Intervention: Chronic renal failure patients with heavy proteinuria
Number of subjects: 20
Study: 10799382

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg) with low-fat spread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg) with high-fat spread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alpha- plus beta-carotene (8 mg) with low-fat spread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alpha- plus beta-carotene (8 mg) with high-fat spread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lutein esters (8 mg lutein) with low-fat spread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lutein esters (8 mg lutein) with high-fat spread
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with low-fat spread
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with high-fat spread
Number of subjects: 15
Study: 8830946

Group type: EXPERIMENTAL
Intervention: High +Gz forces during aerial combat maneuvering for 40 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recumbent rest before flights
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting in an aircraft on the ground
Number of subjects: 20
Study: 1601799

Group type: EXPERIMENTAL
Intervention: Voluntary contractions at 10, 25, 50, 75, 85, and 100% of maximal voluntary contraction (MVC) force
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated contractions produced by supramaximal electrical stimulation of the ulnar nerve at frequencies of 10, 20, 30, 50, 70, and 100 Hz
Number of subjects: 0
Study: 3904886

Group type: EXPERIMENTAL
Intervention: Indalpine 150 mg per day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mianserin 60 mg per day
Number of subjects: 65
Study: 30105510

Group type: EXPERIMENTAL
Intervention: Lusutrombopag 2 mg once daily for 7 days
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lusutrombopag 3 mg once daily for 7 days
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lusutrombopag 4 mg once daily for 7 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61